Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 4:45 PM ET

Biotechnology

Company Overview of Gilead Pharmasset LLC

Company Overview

Gilead Pharmasset LLC, a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. The company primarily focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including PSI-7977, an uracil nucleotide analog polymerase inhibitor, which is initiating a Phase III clinical trials; PSI-938, a guanine nucleotide analog polymerase inhibitor that...

303-A College Road East

Princeton, NJ 08540

United States

Founded in 2004

82 Employees

Phone:

609-613-4100

Fax:

609-613-4150

Key Executives for Gilead Pharmasset LLC

President and Director
Age: 53
Chief Financial Officer and Director
Age: 51
Chief Scientific Officer and Executive Vice President of Pharmaceutical Research
Age: 65
Chief Medical Officer
Age: 47
Senior Vice President of Business Development & Scientific Affairs
Age: 51
Compensation as of Fiscal Year 2014.

Gilead Pharmasset LLC Key Developments

Cipla to Launch Generic of Gilead Pharma's Hepatitis C Drug Sovald

Cipla has started work on launching generic versions of Gilead pharma's Hepatitis C drug Sovald. Hepcvir is the brand name under which Cipla will be selling the drug in India. The price is yet to be decided. Cipla is one of the several Indian companies which have signed a voluntary licence agreement with Gilead to sell generic versions in the Indian market. The decision comes even as Gilead is yet to receive a patent for the drug in India. It is also locked in dispute with the patent office over protection for an ancillary molecule. Sovaldi (chemical name Sofosbuvir) is considered to be one of the most effective drugs for treating Hep C. The drug created a huge controversy when Gilead announced that it will be pricing the drug at $84,000 in the United States. However, in India and other developing countries, the drug is priced at $900 for 12 weeks treatment.

Similar Private Companies By Industry

Company Name Region
TheraVasc, Inc. United States
Genetic BioSystems, Inc. United States
Applied Molecular Transport, LLC United States
Zimmer Orthobiologics, Inc. United States
Cell Targeting Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Gilead Pharmasset LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.